Humberto Antunes and Dewey Andrew Tapped for Board of Director Roles

Asheville, NC (May 3, 2017) – Avadim Technologies Inc. (“Avadim”), the Bionome TherapiesTM life sciences company, announced the results of the Avadim’s Annual Shareholders’ Meeting held in Asheville, North Carolina on April 19, 2017. The shareholders’ vote ratified both the change and appointment of KPMG, LLC as the auditors of the Company, as well as, elected the full slate of nominees for the Avadim Board of Directors.

The Company welcomed Humberto Antunes, who had recently joined the Avadim Board and Dewey Andrew, who was newly-elected at Meeting. Humberto Antunes was previously the CEO of Nestlé Skin Health; Chairman of the Board of Galderma S.A.; Chairman of The Proactiv Company; President and CEO of Gladerma Pharma S.A. and was Vice-Chairman and involved with the American Skin Association for the past 15 years. Newly-elected Board member Dewey Andrew brings his commercial banking, product distribution, healthcare and non-profit experience sets and networks to the Avadim team.

In addition to the Mr. Antunes and Mr. Andrew’s appointment, Chairman & CEO Steve Woody, Avadim’s President David Fann, Senior Vice President Paul Cox, Charles Owen III and Karan Rai were re-elected to the Avadim Board.

Charles Owen III is currently the President of Sirocco Inc; Manager of Fletcher Development Group; President of Fletcher Warehousing, LP; Vice Chairman of the Board of the University of North Carolina Healthcare System; Member of the North Carolina Institute of Medicine, and; former Board Chairman of Mission Health System. Karan Rai is the recent founder and CEO of ASGARD Partners & Co. a merchant banking firm based in New York City; CEO of Theodor Wille Intertrade, Inc; is past-President of ADS Tactical, Inc., and; was previously a Vice President of Investment Banking at JP Morgan.

In the management information sessions following the formal portion Meeting, our shareholders heard a review of the 2016 year as well as recent events at Avadim. Avadim continues to grow and receive endorsements of their products and therapies that have been launched and tested so far, through testimonials, focus groups, and partners and witnessed by increases in revenue. Excitement around Avadim’s near and longer term therapy development pipeline, programs and platforms was a highlight at the Meeting.

For more information on Theraworx®, please visit

About Avadim Technologies Inc.:
Based in Asheville, North Carolina, Avadim is the Bionome TherapiesTM life sciences company. Avadim has created a new health order by eradicating the existing “sick care” approach to deliver true “health care” through topical Bionome TherapiesTM engineered to restore the skin’s natural ecosystem – each with the potential to dramatically enhance the quality of life for a lifetime. People are accepting of today’s standard of care (get sick, treat & repeat) even though it’s inadequate and few companies have stepped up to challenge this simply unacceptable approach that has been in existence for decades. Avadim is the industry leader in delivering true microbiome compliance with effective outcomes. Microbiome compliance ensures the therapy does not negatively effect the colonization of the skin’s microorganisms that human beings depend on to stay alive.

Avadim Technologies Inc. Contacts:
David Fann, President
828.251.7111 Office
904.251.4910 Cell
[email protected]

Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
[email protected]

Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803

Westbury Group Contacts:
Patrick Huddie
[email protected]
T: 443 538 4865

John Jensen
Managing Director
[email protected]
O: 203 267 0268
M: 203 615 1328

James Whitcomb
Managing Director
[email protected]
O: 203 571 3214
M: 917 881 2707

Investor Relations:
KCSA Strategic Communications
Valter Pinto
[email protected]

Media Contact:
Meghan Orencole
Kel & Partners
[email protected]
O: 617.904.9393, ext. 143
C: 857.753.3688